PCRX NASDAQ
Credit Risk of going bust: higher than 57% of companies Debt: 22.1% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.96 (down 97%), Pacira BioSciences, Inc. would be worth roughly what it owes.
Total debt $412.1M against a stock market value of $1.45B.
Distance to default 4.51 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $191.9M (short-term plus half of long-term), stock volatility 51.9%; Altman Z 2.46. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Brisbane, CA 94005
US
Operating within the United States, Pacira BioSciences, Inc. is dedicated to providing healthcare professionals and their patients with non-opioid solutions for pain management and regenerative health. Its offerings include EXPAREL, an injectable liposomal bupivacaine suspension, and ZILRETTA, an extended-release injectable suspension of triamcinolone acetonide. Furthermore, the company offers the iovera system, a non-opioid, handheld cryoanalgesia device capable of delivering precisely controlled cold temperatures to targeted nerves. Pacira also develops its unique multivesicular liposome (MVL) drug delivery technology, which encapsulates therapeutic compounds while preserving their inherent molecular structure. Established in 2006, the firm was formerly known as Pacira Pharmaceuticals, Inc. until its name change to Pacira BioSciences, Inc. in April 2019. Its main corporate office is situated in Tampa, Florida.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| RIKER LAUREN | M-Exempt | 6,000 | $32.35 | 2026-10-08 |
| RIKER LAUREN | S-Sale | 6,000 | $36.32 | 2026-10-08 |
| RIKER LAUREN | M-Exempt | 6,000 | $32.35 | 2026-10-08 |
| SLONIN JONATHAN | S-Sale | 3,040 | $23.23 | 2026-08-17 |
| RIKER LAUREN | S-Sale | 6,115 | $23.50 | 2026-06-11 |